Oruka Therapeutics reports Q3 EPS ($1.46), consensus (40c)
The Fly

Oruka Therapeutics reports Q3 EPS ($1.46), consensus (40c)

“We had a highly eventful third quarter which included going public, closing on over $475 million in proceeds across two transactions and continuing to progress our very promising co-lead programs,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka. “We are excited to soon transition to a clinical stage company and show the potential of our programs to raise the bar on what is possible in psoriatic disease.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App